1adc970c-d433-44d0-aa09-d3834986f7a2 1 there is a 13.2% difference between the results from the two the primary trial cohorts
6b9162d0-0816-46d4-81af-c60028dcc63b 1 Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over
0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f 1 a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis
cc1f712a-2116-4e40-9810-f315e3fa5ff8 0 the primary trial does not report the PFS or objective response rate of its patient cohort
904061c0-14fa-4f13-9118-9a41e24fa8eb 1 Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial
43ee7645-ce1e-42d5-9a74-3e379f6f367b 1 only patients with a HER2-positive status can take part in the primary trial
0cef8c8e-7986-46c7-a597-c5733a9899c0 1 the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months
43ce26e5-03fa-4e9d-b0eb-6ea356295753 0 Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .
3facad41-0221-42f8-834d-470e65c4aad5 1 the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease 
9cbc00e9-3a2d-4471-a93e-72c95132fb6a 0 The only case of congestive heart failure in the primary trial occurred in cohort 1
8b91cab9-d858-45f3-bf8d-3d6fc55b4818 0 The the primary trial results section reports two different measurements
4a75574c-fa86-4e62-a210-81c7b98a3807 1 T4 N2 M4 patients are eligible for the primary trial
d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7 1 The the primary trial results section reports two different measurements, for all 3 cohorts.
b0b61978-57db-4a1c-812c-509e8b05f2dc 0 both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have
24b85b44-b9e6-4c28-b3aa-1bd97102b7f1 0 Patients must have a palpable carcinoma to be included in the primary trial
fbb62216-2cf2-4813-ad41-12a86940610f 0 Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial
961a956e-fece-4baa-a2ad-d3a5320bd9d2 1 The shortest PFS in cohort 1 of the primary trial was less than 3 weeks
97fd111c-6969-43ab-93af-b3dff09960e5 1 The adverse events section in the primary trial is reports the incidence rate of 12 different Aes
eb1bfb08-eba0-4130-b328-00f56c0f84a6 1 Diarrhoea is the most common adverse event in the primary trial and the secondary trial
b1219e71-fbf5-4bba-8a93-a27ae444e3e1 0 to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer
f10f3b84-e039-4a02-a98b-86d149d9a16f 0 ongoing flucytosine treatments are not permitted for participants of the primary trial
0ddb07ae-6e70-436d-8723-f609e59c57da 1 the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight
c10eea1a-5768-442d-ae07-20b4f8f4b583 1 Only patients with triple negative breast cancer are eligible for the primary trial
2ef186d0-b4ab-44de-b785-a63e9e95851a 0 most participants in the secondary trial and the primary trial did not suffer from Enterocolitis
fef5aedb-21c0-4130-b8a3-cb1df5017c7a 0 The adverse events section in the primary trial is empty
2655c892-216e-4b96-a8f2-6f64403215c5 1 there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial
2825d63b-8f22-4fb8-829f-9567845251c6 1 adults and children can take part in the primary trial
6b35bc10-f591-4b84-abac-40a74be949fa 0 Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial
a5baab2c-9c32-4301-a574-4ba5a0c2eb00 1 Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.
70677d5f-7022-404c-8410-d1f89366d92f 1 the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.
f46a7d27-a94f-4389-a1a0-4a8f5177b354 1 None of the individual Aes recorded in the primary trial affect more than than one patient
fe876bb0-7ce3-4197-81ad-920f1f77938e 0 there is a minimal difference between the results from the two the primary trial cohorts
f45ff82d-e0f5-456a-9d78-ddc2dc6ab929 1 to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.
4f705481-5dd0-414c-b375-c56e8c235b42 0 The most common adverse event in the primary trial was skin infection
614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2 1 Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial
c09fa61c-967a-40ae-96b0-c87b7cde237b 0 None of the individual Aes recorded in the primary trial affect more than 10% of the population.
4309860d-042d-45a4-8a0a-a9fdd075247a 1 Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion
f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85 1 the primary trial and the secondary trial use identical outcome measurements
59cd7909-00c3-4c23-9a08-a42dbc8eabdd 0 Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression
e6a4e9a6-56b8-4a30-9743-eb02688c090f 0 A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm
82a3e542-f784-44d7-90f6-34d7e969283c 0 the primary trial participants receive more than one type of medication during the study
fb360514-14be-45ab-8b74-ea5a7eb181d7 0 the primary trial and the secondary trial do not report adverse events
7137dec6-5c98-4156-8035-7bbaaf0b649d 0 ECOG score < 2 is necessary to be eligible for the primary trial
015dd869-db90-45a9-a951-9dc7dc2b2e01 1 patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial
3a4003f6-ff1c-43d8-be48-f767266b2cf5 0 the secondary trial and the primary trial do not have the same inclusion and exclusion conditions
47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7 0 at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months
f3cb9150-32c6-4877-9a87-4fac45a24948 1 Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial
9d8b26d6-d574-4717-88b6-77458bc683f3 1 Syncope was the most common adverse event recorded in the primary trial
51be7c95-8da4-419c-950c-91ebdd2c3fe5 1 All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial
07042b0f-d422-49c3-8d53-81319927a4b3 0 all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial
32361e21-ee57-4c34-9390-833ba5048a10 1 the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally
88668508-dfd4-4a39-91cd-cf1654a6dfc4 1 the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis
dca4c9f7-bb2a-4f73-b390-93b7ced87c73 0 The results from the secondary trial and the primary trial are non-comparable
e7604382-09cd-43b4-998f-a51b33f25c5a 0 the primary trial and the secondary trial participants do not receive any medication orally
75affd49-4905-4d43-9a5c-ef795281bac4 0 neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.
2e76c74a-b6dd-47d8-a674-c1e80b0a3a65 1 to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.
8c6314f7-34f5-42a7-ba66-b95d050a6315 0 The shortest PFS in cohort 1 of the primary trial was 1.4 months below average
f114846e-79d8-4712-add0-bb34b65d418f 1 there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.
812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe 1 the primary trial reports the changes in the number of lesions for patients in its cohorts.
b1d28450-fc7d-496a-9c7c-bf711b28f8e4 1 all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy
c7dc582a-4a58-4cb5-b980-b2d2b6a128c3 0 no cardiac or neural adverse events were recorded in the primary trial
a805f174-2707-4302-a195-05153ea8523e 0 Only adults can take part in the primary trial
e4aeb013-7713-4b73-acbd-f8379cc6a494 0 there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1
b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3 0 All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months
2729a321-709b-4392-9604-dd7237bedb17 0 the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.
8e9611fc-89f8-44cb-af09-8d71a13ca082 0 Cohort 1 and 2 of the primary trial do not receive the same intervention
b9491012-49ba-4eb1-8230-1966f54ea012 0 Patients with Extracranial metastases can be eligible for the primary trial
62e449ad-16b3-479d-94a5-ffc435b5e99c 0 patients with a Malignant brain tumour diagnosis are excluded from the primary trial
565d7982-aa9a-4c01-987c-1d67bc9c212d 1 ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry
7271e0db-bb82-423f-ad95-5ffa84fab97e 0 There are more cases of Urosepsis in the primary trial than in the secondary trial
6402e13a-7cfb-4774-b7f9-80ecb79fda2a 0 the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.
734423d5-4b47-4448-ab98-811015d626f0 1 There were multiple patients which suffered Neutropenia in both cohorts of the primary trial
e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd 1 All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole
32ed503c-1cfd-44f6-b8bb-23d9d175d73d 0 Patients must be able to undergo a PET scan to participate in the primary trial
175044aa-72b1-405d-8506-30002f5098e4 1 There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study
045ad91e-44fa-42cc-ac22-a7aab26a9009 1 the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention
00822101-fa21-4a26-bf45-3b1f535da005 0 a patient with a HER2-positive status can not take part in the primary trial
06f798d1-2956-4903-83e9-58a41fa425f7 0 the primary trial and the secondary trial do not record any cardiac or infection related adverse events
8648c7df-582a-42a9-9330-414b2430ac56 1 none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events
89f610a7-9e81-43a4-8c1e-5503233b2be1 1 Breast cancer patients must have documented stable disease to participate in the primary trial
b0046821-ba27-4a90-8869-cb708b843aa4 0 All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed
d1b217ae-76f3-4ba6-958e-5b2558703ba4 1 several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2
8ddf8b88-6e06-4c71-9e28-45f73a637af0 1 the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.
0ea29bd5-20be-40ea-8ad7-705d283d1d48 1 the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer
e147796d-2edd-42d1-ac53-300fb8bd5eb6 1 80% of patients in the primary trial received a placebo intervention
6b33b4ae-36f2-4a53-a954-6f246f6e023d 0 Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)
06fad978-1dc3-46f5-b45f-5ac6577f28b9 1 Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial
878c09e7-3fd9-404e-921e-5b549e9578fb 0 Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.
3a0c517d-9b9a-4497-9675-50ff12cd02b7 0 in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain
9abb10d7-496e-44fd-915d-d86aedf6c9b6 1 Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)
8460a212-8054-4bd2-b4e6-af1d137a2f79 0 the primary trial and the secondary trial report their results using different units of measure
a3390ae6-d41d-4dc7-899e-de9534adfd6b 0 the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib
17bbea92-8f92-41f3-9b9d-cf6e62cf6798 0 the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.
794269ca-e7ec-4a65-ace5-b0f24a8cdc15 0 the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS
4dfff980-6a2b-4f01-9194-6ec831d6fed7 0 Infections were the most common adverse events recorded in the primary trial
dc4c57b0-8c75-494e-81b0-3528df85ebff 1 neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts
8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c 1 the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response 
251a20d8-2555-4929-9d01-c02311bdc93f 0 a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1
dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1 0 the secondary trial and the primary trial do not record the same metrics in their results section
f0273b8c-460d-46fe-9c52-8ff4b08e439b 0 eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial
bc2024fc-5b39-4fa6-badf-f034d6fe8bb8 0 Breast cancer patients must have documented progressive disease to participate in the primary trial
c2217d42-e90c-4ffe-b084-e653b9ace4d5 1 the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy
080da381-b5dd-46d3-99c4-18112da153c1 1 There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial
c100a7cd-e3a2-4901-a3e0-12336f769c7b 1 the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16
ec1e269e-470d-43d9-8f23-8a19a5c96fcc 1 Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2
21611c2a-e6eb-4012-a209-9b6781e1f260 0 There is no adverse events section in the primary trial
d1b7105d-0b7d-4b10-92a7-d63243ff0629 0 Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger 
7f3fe97e-68ee-470f-b06e-21cdddb67aa8 1 all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial
ce8464bd-951e-44aa-97d9-10b917b055ce 1 there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1
0131ebe3-746b-45a5-ba60-fdd326974fec 0 the primary trial and the secondary trial use comparable outcome measurements
b1dd7632-ed92-40a9-9293-bce68619c658 1 Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible
45ccd2c8-6e02-4f0f-a370-eed18d26e6dc 0 the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally
4a15ec5e-4904-4f01-a0a2-c51e83c8c070 0 the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort
b9e29ea8-6847-40d4-b5c3-81c496101695 1 All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months
2a2c16a7-f427-4fdb-8153-94aac304e4b8 1 Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles
618a3ae1-b22c-4c35-86a6-190c1b5b5d21 0 Patients must have a Life expectancy of at least 1 year to enroll in the primary trial
e62f5a3f-0091-4980-9822-db8f4dc2502a 1 the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts
4a41ac73-538a-43e5-b7ce-8c8e2d56286e 1 Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.
75a65913-5655-4377-b441-ecdd4dd75175 0 Patients with stage 4 cancer are excluded from the primary trial
1329dec6-fb2c-4219-9db6-3fef9d94b316 1 in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain
29b2fa29-5a76-4877-95bb-1a8de7973d33 0 Only 6/67 patients in cohort 1 of the primary trial suffered adverse events
7edba90d-076d-4f55-b9d6-a1765ceb48bd 1 the primary trial and the secondary trial participants do not receive any medication by IV
ba9daeb9-796d-49ab-a30c-4d8acbdf4d37 1 in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin
1314146f-2869-4525-8034-7f732d238385 0 none of the individual adverse events in the primary trial affect more than 100 patients.
7c7418d2-32d7-4517-874b-eb3db24ea16a 0 to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.
1f6a14ae-e22b-4b40-b389-217570dbf38e 0 50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities 
5c1e360c-fd93-4dd4-b855-71ba416d34cb 0 patients must be able to receive medication orally to participate in the primary trial
c7a953b0-ac96-4e0a-9c1d-98cf8af2861d 1 the primary trial and the secondary trial report the same types of adverse events
48f516ff-abb4-4312-9b00-02f53fb16218 1 under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response
978d19fc-e7f6-485e-b8bd-cfcde06441ab 0 T1 N0 M0 patients are eligible for the primary trial
0a6d1b4c-244e-44e2-a229-62e4cbdfa979 0 the results of the secondary trial and the primary trial are non-comparable
9bcc31df-c1f6-4785-9235-f673213acf3a 0 both the primary trial cohorts receive identical doses of Docetaxel 
63a0a9fc-80b9-450f-b2c6-7aee37ce26a9 1 neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention
75cf4ec2-9f2b-4d5b-8772-af247eaca07b 0 Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial
553f00ea-5197-4233-b1e0-e5727856b599 1 no cardiac or bowel-related adverse events were recorded in the primary trial
57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32 1 There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial
215a5c4a-d90c-4500-8284-0679ce311734 1 patients must have HER2- breast cancer to participate in the primary trial
e9a4bd91-f58b-4234-9037-75e0699d1bbd 0 the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate
7d52734c-0801-413d-9ae2-d190b972cde5 1 The results from the secondary trial and the primary trial can be compared by changing the units from days to months
5de9caeb-9dd5-4535-8fe3-289450d9c626 0 the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.
bebfc78e-b35f-4677-8342-9567a7e795a1 0 There is one case of Diarrhea in the secondary trial and none in the primary trial
faa65e54-aa04-4595-8dae-05cf00b4c887 0 Only cohort 1 patients of the primary trial are administered Ipatasertib
751fd763-89fa-4d52-8bda-f09b490a5e78 0 there were no recorded deaths in the primary trial cohorts.
c40fdf91-9f81-454a-bba9-ec5c950cef6e 0 One patient cohort in the primary trial received a placebo intervention
31105b43-832b-48bc-a78d-ee90c155ca44 0 Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.
49ba06b2-576d-4db2-80b6-51673416f2ba 1 the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts
3cb71095-8e01-40dc-bbf5-eeffed55f354 1 Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial
09fc4356-6154-427e-b710-ed5df6470aff 1 50% of cohort 2 patients in the primary trial suffered Keratitis
446f3c69-0de5-475c-a8e2-ff40ece90672 0 Only patients with HER2+ve breast cancer are eligible for the primary trial
cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2 1 the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects
f0e845f9-8991-45b5-a520-51e934756f7a 0 The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.
a0065d58-e03b-4dd0-9c81-cbbf651a6d45 1 any patient eligible for the secondary trial will also be eligible for the primary trial 
b2cdbcb8-de26-4a44-8a94-dd68c13f7e41 1 ECOG score > 2 is necessary to be eligible for the primary trial
973f090a-8967-4d75-bb8e-6166c868337c 1 cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients
79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2 1 Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial
1d1f57f8-85f7-448c-a4bb-15957da568fd 0 the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression
9f7d476e-9db3-4c00-abe6-4c2f0160470a 0 under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response
a5e388b9-da3c-437e-a6af-7ba76ad8bf1d 1 both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo
3adcc8fc-b76b-407a-a006-729a13f571fb 1 both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-
68379456-775b-463b-bfdb-d8aa42c9124b 0 Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial
5d0ccb93-71ec-4079-92c6-d7cbf951a7bb 0 Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial
f04d9695-81b8-4d70-877b-59caddf901bd 0 Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial
f42e1874-343a-43ed-bb0c-884509c4793c 1 the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death
30483d7e-7703-459c-bd10-e2bd259c2a4f 0 there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial
7cde9a22-a91f-4feb-892d-7cbd35f96a27 0 the primary trial reports the changes in tumor size for patients in its cohorts.
16c29502-4683-4087-9410-ff1b786556f5 1 The least common adverse event in the primary trial was Constipation 
5c975af8-6b7f-4a5d-b4a6-257c76763ce9 0 There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial
1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7 1 There were more total AEs in cohort 1 of  the primary trial than cohort 2
8e91e404-086e-4063-8d54-83d1b8ebd969 1 over 1/6 patients in cohort 1 of the primary trial suffered adverse events
b8322b23-a4f6-4cba-9761-be826b509de7 0 There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial
4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3 1 There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts
4b97a844-8d52-48bb-8eda-ca205268f016 1 Patients must have a Life expectancy of 75+ years to enroll in the primary trial
2a03c17f-3afe-40f1-a0db-4b876ee8c700 0 the primary trial and the secondary trial have non-comparable outcome measurements for their results
3ba42f68-a643-4d10-afd0-cbb358d05a6f 0 All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial
0a079cca-abde-42cf-9cec-a76e7a380e14 0 neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention
9c033072-5f94-4d79-af47-126d531f0d6e 1 There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial
a52b2d4f-0b06-4960-a9c3-88cb92df0980 1 the primary trial participants receive Capecitabine less often than they receive Lapatinib
a792bbac-0e8a-4bf7-9cc5-56fad481e2fb 1 eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial
1842904b-5371-49ee-b6f4-8831b879098b 0 Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients
324562e6-2b61-4a07-b937-86f99689f2d5 0 Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial
74e376d7-5713-43f3-93f1-9608059c9547 1 neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications
0e609fad-9a28-4fb6-90b6-32a731e3b02c 1 the primary trial and the secondary trial report their results as perecentages but use different units of measure.
236780db-9e59-4dc9-8da0-e786287011cf 1 the primary trial intervention protocol lasts a total of 14 days
6d621974-c719-46df-8a50-d94e49583e33 0 all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy
a9907a2e-254a-45ca-af50-3e44fd2f7af3 0 There was one case of  Neutropenia in both cohorts of the primary trial
40f699a1-fbc6-40de-8e80-85b28f71632f 1 Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.
6499b181-7a23-4073-8459-ad46ff02b20f 1 Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)
2da13cd4-7189-4f85-be4d-5c1e213ae293 0 The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.
a9bb6de9-c6f8-4c99-81cd-f101cbaab387 1 Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial
7e5fd062-6ec3-480f-ab0e-e117eba2ffe7 0 All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.
016943fa-57ea-4293-8131-03292ea1836c 1 A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm
402f0dbf-cf67-4425-b300-a0a3df4d59d3 0 the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. 
62be4676-099f-4c42-8029-773af8fde6f7 1 Patients must be bedbound or severaly disabled to participate in the primary trial
1180dd58-61b8-4c48-ab00-7d458e68c85b 1 the results of the secondary trial and the primary trial report the same outcome measures
566bdc2d-7c4a-4547-87da-ac81447ecca8 1 the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.
d310ec4e-993e-4827-8dc5-9aca053972db 1 The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.
a5617ae4-05a3-42d0-9e14-141de5f8c010 0 the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any
42d1fcd3-8faa-4065-bbba-42cc90ab67fb 0 the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.
d01fda83-5dc8-4ad5-92b8-7553dabd7046 0 the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse
985bc5a0-bc21-447f-92f1-150e23ede3f5 1 All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions
